Nyxoah

The path to restful nights

Fast Facts

- Founded in 2009 by serial entrepreneur Robert Taub
- Headquartered in Belgium with subsidiaries in Israel, Australia and US
- Led by a strong and experienced Management Team

- Targeting existing, fast growing OSA market
- OSA prevalence worldwide 936 million patients
- 425 million moderate-to-severe OSA patients eligible for therapy[1]

- Raised €79M in equity to date
- Genio®, a user-centered, CE-mark validated bilateral neurostimulation therapy
- Expansive IP portfolio and knowhow

- Large Hypoglossal Nerve Stimulation Market currently underpenetrated
- Yearly eligible HGNS patients – US and Europe/ANZ combined: 1.1 million new patients
- >$20 billion revenue opportunity in Europe/ANZ and US

Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, including Obstructive Sleep Apnea (OSA)

MedTech

- User-centered device development
- Leadless & battery-free neurostimulator
- Bilateral simulation, unique to Nyxoah





Nyxoah

Razor and blades model

- System software upgrade
- Disposable Patch annuity

Patient owning the therapy

- Digital Care Management (DCM) platform integrating diagnostic tools
- Live therapy optimization: Detect/Analyze/Adjust
- AI through data collection

The Genio® system – A novel and disruptive solution

Minimally invasive procedure

Leadless and battery-free

Sustainable compliance & efficacy

Bilateral stimulation

User-centered

Implantable Stimulator

Activation Chip and Disposable Patch

Charging Unit



Addressing unmet needs for OSA patients who have failed conventional therapy, including Continuous Positive Airway Pressure ("CPAP")

Strong Clinical Execution

CE mark approval

>> BLAST OSA – 27 patients

- 2 publications
- CE mark approval in 2019

Demonstrate long-term safety and efficacy

>> EliSA – 110 patients

- 20 EU centers in 5 countries
- 5-year follow-up

Expand Genio® therapeutic indications

>> BETTER SLEEP – 44 patients

- 9 ANZ centers
- CCC represents 25% OSA patients

FDA approval

>> DREAM – 134 patients

- FDA approved IDE pivotal study in June 2020
- Up to 26 centers

[1] Benjafield, Adam V et al. Lancet Respir Med 2019 Aug; 7(8): 687-698

Indication for Use: Genio® is intended to treat adult patients suffering from moderate to severe Obstructive Sleep Apnea (OSA) and who have either not tolerated, have failed or refused Positive Airway Pressure (PAP) therapy.

CE marked since 2019.
Caution – Investigational device in the United States. Limited by United States federal law to investigational use.

Nyxoah S.A.
Rue Edouard Belin 12
1435 Mont-Saint-Guibert
Belgium
info@nyxoah.com
+32 10 22 23 55

Nyxoah